Following Ayotte's Inquiry, CMS Details Mylan's Exploitation

Statement

After asking the Centers for Medicare and Medicaid Services (CMS) this week how the EpiPen price increase has impacted the government's prescription drug costs, U.S. Senator Kelly Ayotte today reacted to news that Mylan Pharmaceuticals exploited a loophole to pay less in drug rebates to the government for EpiPens while enjoying brand-name protections.

"Each new discovery about Mylan's EpiPen actions raises even more questions, and I'm appalled to learn that the company has been profiting off of taxpayer dollars while exploiting a loophole in the rules," said Senator Kelly Ayotte. "It's abundantly clear that Mylan needs to be fully investigated and that CMS needs to address and correct this loophole so it doesn't happen again. I will fight to ensure that we get to the bottom of this situation on behalf of the thousands of Americans and Granite Staters who rely on EpiPens in emergency situations."

Source